Skip to main content
Equibles
VSTM logo

VSTM · Verastem, Inc.

Track VSTM — free

Use VSTM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VSTM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.33 +0.71 (+8.18%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, given the risks associated with these potential strategic or financing opportunities, they are not deemed probable for purposes of the going concern assessment and do not alleviate the substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to generate sufficient net product revenues or obtain additional capital on favorable terms or at all.”
View the 10-Q filed Aug 6, 2026
Market Cap
$806.01M
Shares
90.56M
Volume · Oct 20 2.81M Avg daily vol (3M) 3.05M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.62 Open$8.58 Day$8.51–9.17 52W close$3.45–10.64 Avg vol 30d4.2M Short int15.0M · 16.5% float · 7.0d Short vol52% Last earningsOct 14, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Jan 2, 2027 Est · unconfirmed · in 11 wks
Latest filing: 10-Q
filed Aug 6, 2026
Q2 2026 earnings call transcript
call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$87.53M
Trailing 12 months
Net income (TTM)
−$202.70M
Trailing 12 months
Revenue growth YoY
+1,775.4%
Year over year
Operating margin
-550.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.2%
Year over year · more shares
Price change (1Y)
-6.5%
Trailing year
Short interest
16.5%
Latest settlement · 7.0 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▼100% $2,000 −$22.79M '21 Q3 ▲7.7% $545,000 −$16.48M '21 Q4* ▲158.1% $2.60M −$16.96M '22 Q1 · $10.00M −$8.26M '24 Q2 ▼78.6% $2.14M −$25.93M '25 Q2 · $11.24M −$98.52M '25 Q3 · $18.67M −$36.59M '26 Q1 LATEST ▲1775.4% $40.08M −$34.67M '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +42%
above
Price vs 50-day avg +13%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 72%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +58%
trailing
YTD return +12%
this year
Relative strength +50%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow Accumulating
9 of 159 funds reported for Sep 30 · net +130.8K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.52% of float · ▼ -17.0% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 3-yr high, broad support
Squeeze score 83
high risk · 0–100
Fundamentals
Strong
Revenue growth +209%
Y/Y
EPS growth +17%
Y/Y
Free cash flow $-137.5M
Balance sheet $37.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 77%
annualized · 1-yr
Max drawdown −68%
past year
ATR 8.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 14, 2026
Net product revenue · three months ended September 30, 2026 $23.9M – $24.1M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+42% Bullish
Price vs 50-day avg
+13% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
72% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow Accumulating
9 of 159 funds reported for Sep 30 · net +130.8K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.52% of float · ▼ -17.0% MoM · 7.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
159 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $9 · 72% Range high $11
vs 200-day avg +42% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
COPIKTRA cumulative worldwide net sales milestone $200M Q2 2026 filing —
Non-GAAP adjusted net loss non-GAAP $30.6M Q2 2026 —
Non-GAAP net loss per share (basic) non-GAAP $0.31 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VSTM
Verastem, Inc.
this stock
$806.01M +11.7% +209.1% — 16.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
158
% held
106.0%
Reported
9 of 159
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
135
View
Short & Settlement
Short Interest Falling
Shares short
15.0M
Days to cover
7.0d
Change
-3.1M sh
View
Short Volume
Short vol %
52%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
5.5K
Value
$44.8K
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
30.7%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$30.9M
Net income (FY)
$-209.5M
EPS diluted
$-3.02
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 14, 2026
This year
18

Verastem estimated third-quarter net product revenue of $23.9 million to $24.1 million for the three months ended September 30, 2026; Michael P. Bailey becomes CEO January 1, 2027; VS-7375 showed 41% confirmed ORR in 2L+ PDAC.

View
Proposed Sales
Value
$353.0K
Shares
44.1K
Filed
Oct 1, 2026
View
Exempt Offerings
Offering
$100.0M
Filed
Mar 6, 2020
View
Earnings & Events
Webcasts
Last webcast
Oct 14, 2026
View

Performance

5D 20D 120D MTD YTD
VSTM +4.5% +7.9% +57.9% +7.1% +11.7%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY +6.0% +8.8% +50.2% +6.6% -0.7%
Key facts CIK 1526119 CUSIP 92337C203 13F (30d) 10 filings 10 filers Visit website Investor relations